Conference Coverage

Switch back to human insulin a viable money saver


 

REPORTING FROM ADA 2018

There was no industry funding. Dr. Luo is a consultant for Alosa Health and Health Action International.

SOURCE: Luo J et al. 2018 American Diabetes Association scientific session abstract 4-OR

Pages

Recommended Reading

Pancreatic cancer has a pancreatopathy distinct from type 2 diabetes
Type 2 Diabetes ICYMI
ADA punts photography ban to presenters
Type 2 Diabetes ICYMI
Clinical trials to look for at ADA 2018
Type 2 Diabetes ICYMI
Preview of ADA/EASD statement on hyperglycemia
Type 2 Diabetes ICYMI
Ethical violations scuttle NIH’s big alcohol study
Type 2 Diabetes ICYMI
FDA okays fully implantable continuous glucose monitor/mobile app combo for diabetes
Type 2 Diabetes ICYMI
FDA: MiniMed 670G now available for younger diabetes patients
Type 2 Diabetes ICYMI
Patients going without as insulin prices skyrocket
Type 2 Diabetes ICYMI
Average glucose, A1c discordance is common, highlights ADAG equation concerns
Type 2 Diabetes ICYMI
T1D neuropathy declines as glycemic control improves
Type 2 Diabetes ICYMI